- Motley Fool•yesterday
The potential for ozanimod to reshape multiple sclerosis may be worth billions of dollars in annual sales.
- Motley Fool•2 days ago
Biogen's list price for a new rare-disease drug makes it one of the world's most expensive. Was that a mistake?
- American City Business Journals•3 days ago
The head of the pharmaceutical industry’s biggest Washington lobby group visited Boston on Tuesday as part of a public relations campaign aimed at countering criticism of high drug prices — and singled out Cambridge-based Biogen for praise. During a question-and-answer session with reporters Tuesday, Stephen Ubl, the head of the Pharmaceutical Research and Manufacturers of America, spoke out against what he called a handful of “bad actors” — companies that purchase off-patent medicines that lack generic competition and then significantly raise the price. As an example, he pointed to Biogen’s (BIIB) Spinraza, which in December became the first drug approved to treat spinal muscular atrophy, a leading genetic cause of death in infants.
BIIB : Summary for Biogen Inc. - Yahoo Finance
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||281.50 x 100|
|Ask||284.46 x 100|
|Day's Range||283.41 - 288.11|
|52 Week Range||223.02 - 333.65|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||16.82|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|